Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

The paradox of response and survival in cancer therapeutics.

Huff CA, Matsui W, Smith BD, Jones RJ.

Blood. 2006 Jan 15;107(2):431-4. Epub 2005 Sep 8. Review.

2.

High-dose chemotherapy and autologous bone marrow or stem cell reconstitution for solid tumors.

McGuire WP.

Curr Probl Cancer. 1998 May-Jun;22(3):135-77. Review.

PMID:
9659570
3.

Cancer Stem Cells: From Bench to Bedside.

Jones RJ, Matsui W.

Biol Blood Marrow Transplant. 2007 Jan;13(Suppl 1):47-52.

4.

Strategies to eliminate cancer stem cells: clinical implications.

Huff CA, Matsui WH, Smith BD, Jones RJ.

Eur J Cancer. 2006 Jun;42(9):1293-7. Epub 2006 Apr 27. Review.

PMID:
16644203
5.
6.

Aspects of survival from colorectal cancer in Denmark.

Iversen LH.

Dan Med J. 2012 Apr;59(4):B4428.

PMID:
22459726
7.

INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.

[No authors listed]

Drugs R D. 2007;8(3):176-87. Review.

PMID:
17472413
8.

Beware the Medical-Industrial Complex.

Stevens CW, Glatstein E.

Oncologist. 1996;1(4):IV-V.

PMID:
10388005
9.

Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery?

Jaffe N, Carrasco H, Raymond K, Ayala A, Eftekhari F.

Cancer. 2002 Nov 15;95(10):2202-10.

10.

Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.

Gajdos C, Tartter PI, Estabrook A, Gistrak MA, Jaffer S, Bleiweiss IJ.

J Surg Oncol. 2002 May;80(1):4-11.

PMID:
11967899
11.

Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome.

Elias AD, Skarin AT, Richardson P, Ibrahim J, McCauley M, Frei E 3rd.

Biol Blood Marrow Transplant. 2002;8(6):326-33.

12.

Intensive combined modality therapy for limited-stage small-cell lung cancer.

Elias AD, Ayash L, Frei E 3rd, Skarin AT, Hunt M, Wheeler C, Schwartz G, Mazanet R, Tepler I, Eder JP, et al.

J Natl Cancer Inst. 1993 Apr 7;85(7):559-66.

PMID:
8384264
13.

A systematic overview of chemotherapy effects in ovarian cancer.

Högberg T, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):340-60. Review.

PMID:
11441940
14.

Non-myeloablative stem cell transplantation and donor lymphocyte infusion for the treatment of cancer and life-threatening non-malignant disorders.

Slavin S, Nagler A, Aker M, Shapira MY, Cividalli G, Or R.

Rev Clin Exp Hematol. 2001 Jun;5(2):135-46. Review.

PMID:
11486652
15.

Health-related quality of life in early breast cancer.

Groenvold M.

Dan Med Bull. 2010 Sep;57(9):B4184.

PMID:
20816024
16.

Role of new treatment approaches in defining treatment goals in multiple myeloma--the ultimate goal is extended survival.

Durie BG.

Cancer Treat Rev. 2010 May;36 Suppl 2:S18-23. doi: 10.1016/S0305-7372(10)70008-6. Review.

PMID:
20472184
17.

Clinical implication of targeting of cancer stem cells.

Zhao L, Zhao Y, Bao Q, Niess H, Jauch KW, Bruns CJ.

Eur Surg Res. 2012;49(1):8-15. doi: 10.1159/000339610. Epub 2012 Jul 11. Review.

18.
19.

Treatment of multiple myeloma.

San Miguel JF, Bladé Creixenti J, García-Sanz R.

Haematologica. 1999 Jan;84(1):36-58. Review.

20.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Epub 2002 Apr 12. Review.

PMID:
12042984

Supplemental Content

Support Center